Status:
NOT_YET_RECRUITING
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions:
Non Small Cell Lung Cancer
EGFR Gene Mutation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a single-center, prospective, single-arm, phase II study of Osimertinib combined with Aspirin neoadjuvant therapy for resectable, EGFR mutated non-small cell lung cancer (NSCLC). It is mainly ...
Detailed Description
Lung cancer is currently the leading cause of cancer-related deaths in humans, with its incidence and mortality rates continuously rising. Among them, non-small cell lung cancer (NSCLC) accounts for t...
Eligibility Criteria
Inclusion
- Patients with resectable stage IIA-IIIA lung adenocarcinoma.
- Patients with EGFR sensitizing mutations (Ex19del or L858R).
- Intended neoadjuvant therapy with osimertinib, with an anticipated survival expectancy of more than 3 months.
- ECOG PS 0/1.
- Primary lesion diameter of at least 1 cm.
- Patients who have previously taken or are currently taking aspirin therapy are allowed.
Exclusion
- Currently receiving other anticoagulant therapy.
- Previously treated with systemic therapy for NSCLC.
- Other positive driver mutations, including ALK, ROS1, MET14 exon skipping, BRAF, RET, etc.
- Contraindications to the use of osimertinib and aspirin.
Key Trial Info
Start Date :
September 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT06018688
Start Date
September 15 2023
End Date
September 1 2026
Last Update
September 21 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.